Gov. Shapiro proposes $5M to help people with disabilities find, retain employment
The walk, held at the department's Hiram G. Andrews Center, was meant to support and empower Pennsylvanians with disabilities. In an effort to continue the support, Governor Josh Shapiro's proposed 2025-2026 budget calls for an additional $5 million investment in L&I's Office of Vocational Rehabilitation (OVR).
'At L&I, we're not just raising awareness – we're transforming lives by breaking down barriers for Pennsylvanians with autism and other disabilities,' Jill Moriconi, Director of the Commonwealth Technical Institute at HGAC, said. 'Through our work at HGAC, we're creating pathways to independence and meaningful careers where every person is supported and celebrated. Governor Shapiro's proposed investments in vocational rehabilitation reflect our commitment to building a Commonwealth where disability is not recognized as a limitation, but as a powerful source of innovation, resilience, and strength for our communities and our economy.'
In addition to the proposed $5 million for OVR, some other key proposed investments are:
$1 million to the Centers for Independent Living (CIL) to recruit and hire staff
$5 million to support workforce initiatives to educate, train, and recruit nursing professionals
$12.5 million dedicated to the Workforce and Economic Development Network appropriation, leveraging $10 million in existing funds and $2.5 million in new state funds to train additional workers
$10 million to further boost employment in the behavioral health sector by expanding the Primary Care Loan Repayment Program at the Department of Health (DOH), broadening the program's geographic eligibility requirements and making it available to behavioral health care workers in all regions of Pennsylvania and
$55 million to support childcare workforce recruitment and retention grants; this would provide roughly $1,000 more annually per employee to licensed childcare centers in the Child Care Works program.
Currently, the budget has yet to be approved.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 days ago
- Associated Press
Prolon L-Protein Bar Sets New Standard for Clean, Age-Supportive Nutrition
L-Nutra's newest innovation is a plant-based protein bar formulated to support muscle health and slow age-related nutritional triggers, not just fuel fitness L-Nutra, a global leader in nutrition technology and longevity science, is once again redefining what precision nutrition can do with the launch of the Prolon® L-Protein Bar — a clean, plant-based bar scientifically formulated to provide the perfect balance of amino acids from plant-based sources to support both muscle health and healthy aging, not just workouts. Most protein products today are focused on quantity — more grams, more calories, more bulk. But emerging longevity science shows that too much of the wrong kind of protein can accelerate aging by overstimulating key growth pathways like IGF-1 and mTOR. On the other hand, too little protein — especially in strict vegan diets — may fail to adequately support muscle maintenance and overall strength. Achieving this balance is critical: while excessive protein, particularly from animal sources, may overstimulate pro-aging pathways, too little protein can undermine strength, energy, and overall resilience. The L-Protein Bar is carefully designed to navigate this middle path — delivering the right nutrients, in the right amounts, from the right sources. Now part of the Prolon suite of clinically informed nutrition tools, the L-Protein Bar continues L-Nutra's mission to create smarter everyday nutrition solutions rooted in more than two decades of research. 'If you want to live a long and healthy life, you need to slow the rate of aging every day — and that starts with what you eat,' says Dr. Joseph Antoun, a Harvard- and Johns Hopkins-trained physician and CEO of L-Nutra. 'Protein can accelerate aging if you're choosing the wrong types or the wrong amounts. Our novel L-Protein Bar, rooted in more than 25 years of longevity science, strikes the optimal balance: enough to support muscle strength, but not so much that it speeds up the aging process. And unlike most protein products, there are no hidden ingredients. We pride ourselves on quality ingredients and transparency in how we make our products.' A Protein Bar Built for the Future of Health Formulated by scientists at the USC Longevity Institute, the Prolon L-Protein Bar includes a diverse blend of plant-based proteins (from black beans, chickpeas, and peas) and is fortified with L-methionine, an essential amino acid typically low or missing in vegan diets and other vegan protein supplements. This targeted formulation is designed to maintain a balanced growth factor response while delivering complete protein support for muscle and tissue health. Each bar contains 14 grams of protein, only 170 calories, and is made without added sugars, sugar alcohols, or artificial sweeteners. Instead, it's naturally sweetened with whole dates for a rich flavor and more balanced glycemic response. How Our Protein Bar Redefines the Standard The bar launches in its first flavor, Chocolate Coated, featuring a 100% dark chocolate layer and a rich, satisfying taste. Additional flavors are planned as part of Prolon's expanding Longevity Nutrition platform — a product suite designed to help people integrate clinically-backed, health-supportive nutrition into daily life. The Prolon L-Protein Bar is now available for purchase at About L-Nutra L-Nutra is the global leader in nutri-technology, advancing the discovery, design, and delivery of clinically tested Nutrition for Longevity and Nutrition as Medicine programs. With over 134 issued patents and more than 47 published clinical studies in collaboration with 18 leading universities, L-Nutra's innovations harness the power of plant-based nutrition to support healthy aging, metabolic reset, and cellular rejuvenation. Through its consumer division, Prolon, L-Nutra offers a suite of fasting and longevity-focused products designed to reduce biological age and support whole-body wellness. Its medical division, L-Nutra Health, delivers clinically backed programs aimed at supporting the remission and regression of chronic conditions like type 2 diabetes and metabolic conditions through food-led, lifestyle medicine interventions. Together, these branches reflect L-Nutra's mission to transform what's possible through nutrition and longevity science. To learn more, visit Media Contact Melanie Murphy Richter [email protected] ### SOURCE: L-Nutra Copyright 2025 EZ Newswire
The Hill
5 days ago
- The Hill
Democrats press UnitedHealth Group over nursing home policies
Democratic Sens. Ron Wyden (Oreg.) and Elizabeth Warren (Mass.) are launching an investigation into UnitedHealth Group (UHG) over its actions reportedly steering seniors away from hospital visits for the sake of cutting costs. In a letter to UHG CEO Stephen J. Hemsley, Wyden and Warren cited reporting from outlets including The Guardian that said his company was paying nursing homes to reduce hospital transfers of sick patients. The senators wrote that UHG representatives told them bonus programs for nursing homes are offered to encourage 'adherence to certain quality measures.' One of these programs allows for nursing homes to receive bonuses if they reach certain levels of influenza and pneumococcal vaccination rates and cholesterol medication adherence rates, while also maintaining a hospital admission per thousand rate below a certain threshold. They also pointed to UHG institutional special needs plans, provided through its subsidiary Optum, which reportedly disincentivize 'medically-necessary hospitalizations and emergency room visits.' These plans also reportedly pressure nursing home residents to sign 'do not resuscitate' (DNR) and 'do not intubate' (DNI) orders. At the time of The Guardian's reporting in May, UHG denied it was preventing hospital transfers or pushing patients to sign DNRs and DNIs. 'Put simply, these allegations suggest that UHG appears to be prioritizing its bottom line at the expense of the health and safety of nursing home residents enrolled in UHG I-SNPs. Nursing home residents and their families should not live in fear of a for-profit health care company withholding care when it is most critical,' the lawmakers wrote. Though they expressed their support for evidence-based models that reduce 'unnecessary hospitalizations of nursing home residents,' Wyden and Warren noted a briefing with UHG representatives did not resolve their concerns surrounding these reports. The lawmakers requested information on UHG's I-SNP model, Optum's policies on transferring residents on I-SNP to the hospital as well as information on its bonus programs. 'Any attempt to take advantage of vulnerable nursing home residents is unacceptable, especially to pad a for-profit insurance company's revenues. It is vital that UHG respond to these alarming reports and provide prompt, detailed responses to our questions,' wrote Wyden and Warren.
Business Upturn
6 days ago
- Business Upturn
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications Annamycin currently in late-stage clinical development in combination with cytarabine for the treatment of AML; Anticipated preliminary data readout in 2H 2025 HOUSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the presentation of encouraging preclinical data for its lead drug candidate, Annamycin, also known by its non-proprietary name of naxtarubicin, which demonstrated significant efficacy against various primary and metastatic liver cancers, including hepatocellular carcinoma (HCC), colorectal liver metastases, and pancreatic ductal adenocarcinoma (PDAC) liver metastases. This is believed to be the result of targeted accumulation in the liver and other organs. These findings were highlighted in a poster titled ' Liposomal Annamycin (L-ANN) Efficacy Against Primary and Metastatic Liver Cancers , ' presented by Dr. Waldemar Priebe, Lead Author and Chairman of the Scientific Advisory Board at Moleculin at the recently held Shelby-Lavine Pancreatic Cancer Symposium at MD Anderson Cancer Center. Key Highlights Targeted Accumulation in Organs: The preclinical studies confirmed that Annamycin exhibits distinct organotropic properties, leading to significantly higher concentrations in the liver, spleen, lungs, and pancreas when compared to doxorubicin (DOX). This targeted accumulation is critical for effectively treating liver-localized tumors. The preclinical studies confirmed that Annamycin exhibits distinct organotropic properties, leading to significantly higher concentrations in the liver, spleen, lungs, and pancreas when compared to doxorubicin (DOX). This targeted accumulation is critical for effectively treating liver-localized tumors. Efficacy in Orthotopic Hepatocellular Carcinoma (HCC) Models: Annamycin demonstrated excellent anti-tumor activity in orthotopic HCC models (Hepa 1-6 Luc), showing a marked reduction in tumor progression and improved survival rates in treated animals compared to vehicle controls. Annamycin demonstrated excellent anti-tumor activity in orthotopic HCC models (Hepa 1-6 Luc), showing a marked reduction in tumor progression and improved survival rates in treated animals compared to vehicle controls. Potent Impact on Colorectal Liver Metastasis: In an experimental liver metastatic model of colorectal carcinoma (CT26 Luc), Annamycin significantly inhibited metastatic growth and extended survival, highlighting its potential for addressing liver metastases in colon cancer that affects close to 50% of patients. In an experimental liver metastatic model of colorectal carcinoma (CT26 Luc), Annamycin significantly inhibited metastatic growth and extended survival, highlighting its potential for addressing liver metastases in colon cancer that affects close to 50% of patients. Promising Results in Pancreatic Cancer Liver Metastasis: Annamycin also showed compelling efficacy in liver-implanted human pancreatic ductal adenocarcinoma (MIA PaCa-2), leading to inhibition of tumor growth, suggesting its potential role in managing advanced pancreatic cancer with liver involvement. Annamycin also showed compelling efficacy in liver-implanted human pancreatic ductal adenocarcinoma (MIA PaCa-2), leading to inhibition of tumor growth, suggesting its potential role in managing advanced pancreatic cancer with liver involvement. Favorable Safety Profile: Consistent with previous preclinical and clinical findings, Annamycin continued to show low or no cardiotoxicity, a significant advantage over traditional anthracyclines like doxorubicin, which are often limited by dose-dependent cardiac side effects. This safety profile was previously observed in clinical trials, where 32 out of 42 subjects reviewed received more than the FDA-established lifetime maximum allowable level of anthracycline without evidence of cardiotoxicity. 'We are incredibly encouraged by these preclinical results, which further validate Annamycin's potential as a powerful and differentiated therapeutic agent for liver cancers,' said Dr. Priebe. 'The ability of Annamycin to concentrate effectively in the liver, combined with its demonstrated efficacy across multiple aggressive liver cancer models and its favorable cardiotoxicity profile, positions it as a highly promising candidate for patients facing these devastating diseases. We believe these data provide a strong foundation for advancing Annamycin in clinical development for these indications, offering new hope where treatment options are often limited.' Walter Klemp, Chairman and CEO of Moleculin, added, 'We continue to be strongly encouraged by the potential of Annamycin. Beyond our preliminary programs in AML and soft tissue sarcoma lung metastases (STS lung mets), we continue to advance and develop Annamycin through multiple investigator-initiated studies to further unlock its potential as a treatment option for many other types of cancers. We believe this preclinical data highlights that potential and provides additional validation of its unique pharmacological profile and importantly showcases the opportunity for its use across a wide range of cancers.' Moleculin's novel drug candidate is being positioned to become the first ever non-cardiotoxic anthracycline to be approved and is currently being developed for the treatment of AML and STS lung mets. For more information, please visit About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit and connect on X, LinkedIn and Facebook. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the whether the preclinical results described above are able to be reproduced in clinical trials. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company's ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. 'Risk Factors' in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775 [email protected]
